GlassScriptPhysician profile
Kaitlyn E Richards
NPI 1205300191
$9,471.93
in general payments reported to CMS, 2019-2025
37 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,522 · 2022: $3,088 · 2023: $3,299 · 2024: $313 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,808 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,807.73 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,652.77 | 2021-2025 | Otezla, Enbrel, Tavneos |
| Janssen Biotech, INC. | $1,118.91 | 2021-2023 | Simponi Aria, Tremfya, Simponi |
| Abbvie INC. | $1,105.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $843.76 | 2021-2024 | Saphnelo, Airsupra |
| Ucb, INC. | $700.10 | 2021-2023 | Cimzia |
| Glaxosmithkline, LLC. | $612.01 | 2021-2025 | Benlysta, Bexsero, Arexvy |
| Horizon Therapeutics Plc | $538.87 | 2021-2023 | Krystexxa |
| Pfizer INC. | $520.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $426.91 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.74 | 2021-2023 | Ofev, Cyltezo |
| Janssen Scientific Affairs, LLC | $319.36 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $208.48 | 2021-2023 | Uptravi |
| Lilly USA, LLC | $197.51 | 2021-2025 | Taltz, Olumiant, Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $119.82 | 2023 | Arcalyst |
| Aurinia Pharma U.S., INC. | $89.88 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $74.79 | 2021 | |
| Ferring Pharmaceuticals INC. | $62.94 | 2022-2023 | Euflexxa |
| Sobi, INC | $58.14 | 2021-2022 | |
| Lundbeck LLC | $54.30 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $48.99 | 2022-2025 | Eliquis |
| Novo Nordisk INC | $45.51 | 2024-2025 | Rybelsus, Ozempic |
| Genentech USA, INC. | $35.46 | 2023 | Actemra |
| Phathom Pharmaceuticals, INC. | $29.57 | 2024 | Voquezna |
| Organon LLC | $28.02 | 2023 | Hadlima |
| Abbott Laboratories | $27.50 | 2025 | Freestyle Libre 3 |
| Sandoz INC. | $27.22 | 2023 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $24.10 | 2023 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $21.19 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.02 | 2024 | Xifaxan |
| Genzyme Corporation | $19.90 | 2021 | |
| Cipher Pharmaceuticals US LLC | $19.82 | 2025 | Natroba, Spinosad |
| Fidia Pharma USA INC. | $18.70 | 2023 | Triluron, Hymovis |
| Depuy Synthes Sales INC. | $18.54 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.44 | 2022 | |
| Currax Pharmaceuticals LLC | $14.88 | 2024 | Contrave |
| Pacira Therapeutics, INC. | $14.67 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.81 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.